Viracta Therapeutics (VIRX) announced that the company has implemented a reprioritization of resources intended to enhance the company’s focus on its Nana-val development program in patients with relapsed or refractory EBV-positive peripheral T-cell lymphoma. To further align resources with current pipeline priorities, Viracta is announcing that it has implemented a further reduction in force that impacts approximately 42% of the company’s employees. Viracta expects to recognize approximately $0.7M in total expenses for severance and related benefits for employees impacted by the reduction in force. Viracta also announced a reduction in the size of its board of directors, from ten seats to six following the voluntary resignation of four directors, Jane F. Barlow, Jane Chung, Sam Murphy and Stephen Rubino, effective October 31.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIRX: